| Date Filed | Type | Description |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/20/2023 |
8-K
| Quarterly results |
| 06/29/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Bought 617,382 shares
@ $0.84, valued at
$518.6k
Bought 575,195 shares
@ $0.84, valued at
$483.2k
|
|
| 06/29/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 14.7% stake in Passage BIO, Inc. |
| 05/26/2023 |
4
| Woiwode Thomas (10% Owner) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
| 05/26/2023 |
4
| Porter Derrell (Director) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
| 05/26/2023 |
4
| Kapadia Sandip (Director) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
| 05/26/2023 |
4
| Kamarck Michael E. (Director) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 21,567 options to buy
@ $1, valued at
$21.6k
|
|
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
4
| Islam Saqib (Director) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
| 05/26/2023 |
4
| GOWEN MAXINE (Director) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
| 05/26/2023 |
4
| Countouriotis Athena (Director) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Investor presentation, Quarterly results |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/06/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 04/05/2023 |
4
| Chou William (President and CEO) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 608,615 options to buy
@ $1.08, valued at
$657.3k
|
|
| 04/05/2023 |
4
| King Simona (CFO) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 140,000 options to buy
@ $1.08, valued at
$151.2k
|
|
| 04/05/2023 |
4
| Forman Mark S (Chief Medical Officer) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 175,000 options to buy
@ $1.08, valued at
$189k
|
|
| 04/05/2023 |
4
| Cale Edgar B. (GC & Corporate Secretary) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 175,000 options to buy
@ $1.08, valued at
$189k
|
|
| 04/05/2023 |
4
| Fotopoulos Alexandros (Chief Technical Officer) has filed a Form 4 on Passage BIO, Inc.|
Txns:
| Granted 175,000 options to buy
@ $1.08, valued at
$189k
|
|
| 04/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|